GlaxoSmithKline : Unit Gets European Marketing Authorization for HIV Medication for Children | MarketScreener

Wednesday, 13 January 2021, 16:01:05
| January 13, 2021
— MarketScreener

British drug giants ramp up battle against Covid-19 with a race for vaccine approvals

Wednesday, 13 January 2021, 00:52:35
On a day of major developments, Glaxosmithkline said it was joining an NHS study to test a breakthrough antibody treatment. The drug – known as Vir-7832 -could be a game changer.
— This is Money

Glaxo aims to double blockbusters to revive portfolio

Tuesday, 12 January 2021, 21:44:46
GlaxoSmithKline Plc set an ambitious goal of more than doubling the number of blockbusters in its portfolio by 2026 as the British pharma giant moves to revive its product lineup.
— Gulf-Times

Small Cell Lung Cancer Therapeutics Market Covering Prime Factors and Competitive Outlook till 2027 | Sanofi, Bristol-myers Squibb, Glaxosmithkline, Menarini, Ziopharm Oncology, Merck, Astrazeneca

Tuesday, 12 January 2021, 15:44:20
Market Research Intellect have recently published a new report on the global Small Cell Lung Cancer Therapeutics market. The study provides profound insights into updated market events and market trends. This, in turn, helps one in better comprehending the market
— OpenPR

The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue

Tuesday, 12 January 2021, 14:15:54
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 11) 10X Genomics Inc (NASDAQ: TXG ) AbbVie Inc (NYSE: (ABBV) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) (reacted to the company's preliminary fourth-quarter results) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Biodesix Inc (NASDAQ: BDSX ) C4 Therapeutics Inc (NASDAQ: CCCC ) CareDx Inc (NASDAQ: CDNA ) (announced preliminary fourth-quarter results) Celsius Holdings, Inc. (NASDAQ: CELH ) Chimerix Inc (NASDAQ: CMRX ) Curis, Inc. (NASDAQ: CRIS ) Dyne Therapeutics Inc (NASDAQ: DYN ) (announced positive preclinical data from its myotonic dystrophy type 1 program) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (announced positive data from midphase study of its investigational asset in treating early symptomatic Alzheimer's) ESSA Pharma Inc (NASDAQ: EPIX ) EXACT Sciences Corporation (NASDAQ: EXAS ) (reacted to preliminary fourth-quarter results) Eyenovia Inc (NASDAQ: EYEN ) Guardant Health Inc (NASDAQ: GH ) Johnson & Johnson (NYSE: JNJ ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Oxford Immunotec Global PLC (NASDAQ: OXFD ) Pacira Biosciences Inc (NASDAQ: PCRX ) Supernus Pharmaceuticals Inc (NASDAQ: SUPN ) Syneos Health Inc (NASDAQ: SYNH ) Theratechnologies Inc (NASDAQ: THTX ) Twist Bioscience Corp (NASDAQ: TWST ) United Therapeutics Corporation (NASDAQ: UTHR ) Vascular Biogenics Ltd (NASDAQ: VBLT ) Xencor Inc (NASDAQ: XNCR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Jan.
— Benzinga